Related Experiment Videos
Chronic sympathetic suppression in the treatment of chronic congestive heart failure
A J Manolis1, C Olympios, M Sifaki
1Tzanio Hospital, Piraeus, Greece.
Insights
Clonidine treatment for congestive heart failure (CHF) significantly improved exercise tolerance and heart function. This long-term study also showed reduced arrhythmias, suggesting improved electrophysiologic stability in CHF patients.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Congestive heart failure (CHF) is a chronic condition with significant morbidity.
- Previous studies indicated short-term hemodynamic benefits of clonidine in CHF patients.
Purpose of the Study:
- To evaluate the long-term effects of oral clonidine on functional status and electrophysiologic stability in patients with congestive heart failure.
Main Methods:
- A longitudinal study of 12 CHF patients treated with oral clonidine (0.075 or 0.15 mg twice daily) for an average of 13 months.
- Functional capacity, echocardiographic parameters, and electrophysiologic data (heart rate variability, arrhythmias) were assessed at baseline and follow-up points.
Main Results:
- Clonidine treatment led to significant improvements in New York Heart Association (NYHA) class and exercise tolerance.
- Ejection fraction increased, and left ventricular dimensions decreased, indicating improved cardiac function and structure.
- Electrophysiologic parameters showed reduced heart rate and a diminished propensity for malignant arrhythmias, including premature ventricular contractions and ventricular tachycardia.
Conclusions:
- Chronic central sympathetic suppression with clonidine offers significant functional benefits and enhances electrophysiologic stability in patients with congestive heart failure.
- These findings support clonidine as a potential long-term therapeutic option for managing CHF.
Abstract:
Previous short-term studies demonstrated that treatment with clonidine produced significant hemodynamic improvement in patients with congestive heart failure (CHF). In this study we followed 12 CHF patients (10 M, 2 F age 63+/-11, 10 with ischemic cardiomyopathy and 2 with dilated cardiomyopathy) treated with 0.15 or 0.075 mg oral clonidine twice daily for 13+/-5 months (range 6-23). with functional evaluation at baseline, 6 weeks and 6 months. There was suppression of circulating catecholamines, associated with significant ameliorations in NYHA class, in duration of exercise tolerance (from 246+/-68 sec to 362+/-30 and 459+/-70 sec, respectively p < 0.02), in ejection fraction (from 32+/-7% to 35+/-5 and 39+/-7% p < 0.04) and in left ventricular enlargement as assessed echocardiographically. There were also improvements in a number of electrophysiologic parameters calculated by computerized analysis of ambulatory ECG tapes, such as heart rate variability, indicating diminished propensity to malignant arrhythmias, as confirmed by decreases in the numbers of isolated premature ventricular contractions, couplets and episodes of non-sustained ventricular tachycardia. The data suggest that chronic central sympathetic suppression with clonidine in CHF results in significant functional amelioration and improved electrophysiologic stability.